secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001171843-25-003854
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports safety, CRs, MRD negativity in TUSCANY triplet for newly diagnosed AML
--------------------------------------------------------------------------------

- Ten newly diagnosed AML patients dosed in TUS+VEN+AZA triplet at 40, 80, 120 mg TUS; no DLTs observed.
- At 40 mg, 3 of 4 patients achieved CRs and MRD negativity, including FLT3-ITD, FLT3-WT, and TP53/CK.
- At 80 mg, all 3 patients achieved composite CRs (CR/CRi); one TP53-mutated/CK patient had early CRi.
- No treatment-related deaths; all 10 subjects remain alive; no prolonged myelosuppression or QT prolongation.
- Data presented at EHA 2025; TUS+VEN+AZA well-tolerated with standard of care dosing; enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003854/0001171843-25-003854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003854/f8k_061125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer